Clinical trial IJB_2691
Phase 3 Randomized Study Comparing Nivolumab and Ipilimumab Combination vs Placebo in Participants with Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse
Cancers | |
---|---|
Organ | Kidney |
Trial status | Trial closed for recruitment |
Investigator | |
Trial type |
Interventional with experimental drug
|
Phase | Trial phase 3 |
Academic trial | Non |
Sponsor | BMS - Bristol Myers Squibb int. |
EudraCT Identifier | 2016-004502-34 |
ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03138512 |
Inclusion criteria | "Adjuvant", healthy margin |
Last update |